Breaking News

Watson to Acquire Actavis

April 26, 2012

Expands international presence, generic injectable business

Watson Pharmaceuticals has entered into an agreement to acquire Actavis Group for approximately $5.6 billion, expanding its international presence as one of the world's biggest generic drug suppliers. The acquisition also enhances Watson's business in generic injectable cancer drugs. The transaction is expected to close in the fourth quarter.

Under the agreement, Watson will make an upfront payment of $5.6 billion. Actavis stakeholders are also eligible to receive a payment valued at $330 million during negotiations should Actavis achieve certain 2012 performance targets.

"In a single commercially compelling transaction, we more than double Watson's international access and strengthen our commercial position in key established European markets as well as exciting emerging growth markets, including Central and Eastern Europe and Russia," said Watson chief executive officer Paul Bisaro.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus